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One of the debate sessions during the recent IHPBA
World Congress in Tokyo was dedicated to the extent of
resection for pancreatic cancer. Under the title ‘Extended
resection for pancreatic adenocarcinoma: Yes or no?’, the
current status of extended radical resection for pancreatic
adenocarcinoma: was put into perspective. The frame-
work of the debate was provided by the panellists and
basically covered the views held at the Academic Medical
Center in Amsterdam and at the University Hospital in
Nagoya. One might say in the end that the whole issue
of extended radical resection comes down to a discussion
between Japanese pancreatic surgeons and their Western
colleagues.
Reports in the late 1980s on the outcome of manage-
ment of pancreatic cancer were not very encouraging [1].
Subsequently experience has increased with Kausch-
Whipple pancreatoduodenectomy (according to the
Italians, Codivilla is entitled to this eponym too, [2]), and
the mortality rate of surgical treatment has dropped to less
than 2% in high-volume centres. When considering sur-
vival after resection, however, we are looking at five-year
survival rates of 5–20 per cent at best and, as sometimes
pointed out by our non-surgical colleagues, we can ask our-
selves if we are really doing a good job. Clearly, this dismal
outcome is caused, apart from liver metastasis, by the high
rate of local recurrence encountered after resection of these
tumours. Lymphatic spread, neural invasion, soft tissue
infiltration and involvement of adjacent structures are
crucial factors underlying recurrence, and obviously expec-
tations were high that by extending surgical resection, next
to development of effective (neo)adjuvant treatment pro-
tocols, survival could be improved. This notion triggered a
modification of the technique of pancreatoduodenectomy,
aiming at extending the limits of the standard resection
initially set out by the Kausch-Whipple operation.
The concept of wide lymphatic clearance in the surgi-
cal treatment of pancreatic cancer was pioneered by Dr JG
Fortner in the early seventies. He introduced radical
excision encompassing wide dissection of lymph nodes,
extended resection of soft tissue as well as nerve plexus and
vascular removal and reconstruction [3]. One third of
patients in his series had lymph node metastases that would
have not been included with the standard resection,
proving his point of extending lymphadenectomy with
resection. However, the toll of this extensive surgical pro-
cedure was an increased morbidity and mortality rate, and
for this reason the technique of wide excision at that time
was not taken up by many surgeons. Fortner called the
technique of wide excision for pancreatic cancer ‘regional
resection’, a term that may now raise confusion in light of
later nomenclature in which regional lymphadenectomy
refers to a limited lymph node dissection as opposed to
radical lymphadenectomy.
In the late 1980s, the technique of extended lympha-
denectomy was picked up again by Japanese surgeons. The
rationale for extended radical resection was based on the
high incidence of intra- and extrapancreatic neural invasion
(65%) [4] in pancreatic cancer as well as the high incidence
of lymph node metastases (50–75%) [5] found in various
(mainly Japanese) studies. Several reports showed
improved survival times (three-year survival rate 38% [6]
and five-year survival rate 33.4% [7], but these were all
non-controlled studies. Interestingly, one report demon-
strated improved survival with extended radical resection
in lymph node-negative patients[8].
What is the available evidence to justify adoption of
extended radical lymphadenectomy? To begin with, there is
no level I evidence that extended radical lymphadenec-
tomy results in improved survival. There are two ran-
domised clinical trials (RCTs) addressing this question, but
one may argue whether these studies meet the criteria to
qualify as level II evidence. The first RCT has been under-
taken by the Baltimore group as a prospective, single-
institution study. According to an interim analysis, 114
patients with periamullary cancer were included in this
study of which only 34, however, had pancreatic ductal
carcinoma [9]. No significant differences were found in sur-
vival of patients after standard resection or radical resec-
tion. Apart from the fact that this study is underpowered
with respect to the number of patients with pancreatic
ductal carcinoma, the resection carried out in this study is
less extensive than understood with the extended radical
type of resection: Only the lymph nodes on the right lateral
aspect of the superior mesenteric artery (not all station #14
nodes) are removed, while the lymph nodes of the coeliac
axis (station #9) are not always removed nor yet the para-
aortic lymph nodes (station #16).
The second RCT is a prospective, multicentre trial
coordinated by Pedrazzoli, including 81 patients with
pancreatic head carcinoma [10]. Forty patients were
randomised to resection with standard lymphadenectomy
and 41 to resection with extended lymphadenectomy. The
latter procedure comprised removal of lymph nodes along
the aorta from the diaphragmatic hiatus to the origin of the
inferior mesenteric artery (whereas the Japanese consider
extended lymphadenectomy to include all the lymph nodes
of station 16, onto the aorto-common iliac bifurcation). No
difference in overall survival between the two groups was
found. This study has been criticised for several reasons.
Firstly, no power analysis underlies this study, potentially
giving rise to a type 2 statistical error. Secondly, the
number of extra lymph nodes retrieved with extended
lymphadenectomy was considered modest (13.3 lymph
nodes in the standard lymphadenectomy group versus
19.8 in the extended lymphadenectomy group). Together
with an operation time that was not significantly different
and a relatively low incidence of postoperative diarrhoea
(25–20%) in the group with extended lymphadenectomy,
there are concerns as to the completeness of the wider
lymphadenectomy performed in this study. A trend
towards longer survival (p = 0.05) in node-positive patients
was found in a post hoc analysis of this study, but on
methodological grounds should be rejected.
This leaves us with no solid evidence that extended
radical lymphadenectomy leads to better survival after pan-
creatoduodenectomy for pancreatic head adenocarcinoma.
Non-randomised studies have shown either prolonged
survival or no advantage for extended lymphadenectomy
[11, 12]. Resection of a segment of the portal vein or
superior mesenteric vein is dictated by the location of the
tumour vis-à-vis the portal venous system and is not neces-
sarily part of extended radical resection. Clearly, the
problem is that variation in patient selection, variation in
surgical technique, variation in terminology and variation
in adjuvant protocols will lead to variation in patient out-
come. The single, most important point therefore, is
standardisation before any attempt at a new RCT should be
made.
Regarding standardisation of terminology, an important
step forward has been made during an international con-
sensus meeting on surgical procedures in pancreatic cancer,
held in Italy in 1998 [13]. A group of 29 experts in the field
of pancreatic cancer, both surgeons and pathologists,
reached an agreement on the definitions of standard, radi-
cal and extended radical pancreatoduodenectomy in terms
of the scope of lymphadenectomy. The standard resection
comprises regional lymphadenectomy around the duode-
num and pancreas including the lymph nodes on the right
side of the hepatoduodenal ligament, the right side of the
superior mesenteric artery, and the anterior and posterior
pancreatico-duodenal nodes, in addition to the usual
(pylorus-preserving) Kausch-Whipple resection. The
radical resection includes regional lymphadenectomy plus
skeletonization of hepatic arteries, superior mesenteric
artery between aorta and inferior pancreaticoduodenal
artery, dissection of the coeliac trunk and anterolateral
Gerota’s fascia. The extended radical resection encompasses
radical lymphadenectomy plus clearance of the lymph node
groups of station #16, between the diaphragmatic hiatus
(above the coeliac trunk) and the origin of the common
iliac arteries. The ideal study would then be a multicentre
RCT with sufficient power, standardised surgical and
pathological methods and involving no form of adjuvant
therapy, to compare standard pancreatoduodenectomy with
extended radical pancreatoduodenectomy, in which a
strong emphasis should be placed on the assessment of
quality of life. It goes without saying that this type of study
is extremely difficult to carry out, and that is why many a
review will still end with the proverbial statement that
properly conducted, randomised controlled studies are
necessary before concluding on the issue of extended
radical pancreatoduodenectomy.
Even if we should succeed in putting together the ideal
multicentre RCT, we may still be confronted with a
controversial outcome. Looking at the Dutch gastric cancer
trial completed in 1998, in which 996 patients were
randomised to undergo either a D1 or D2 gastric resection
according to the Japanese guidelines, no difference in sur-
vival was found [14]. Despite the fact that all the D2
operations were performed by a small number of surgeons
trained under Japanese supervision, critics have attributed
the negative outcome of this trial to a difference in surgical
technique. So one might conclude that there are some
innate believers in extended lymph node excision out
there, who will not easily concede to the results of even a
properly, conducted multicentre, RCT.
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Remarkably, the discussants from Japan showed some
reservation concerning the removal of all station #16
lymph nodes with pancreatoduodenectomy, especially
when lymph nodes of these groups are found to be tumour-
positive during the operation. There is now a multicentre
RCT underway in Japan, conducted by Dr Y Nimura of
Nagoya University Hospital, in which patients with
pancreatic adenocarcinoma who do not have any evidence
of involved para-aortic lymph nodes on frozen section
examinations during the operation are randomised to
undergo either a radical or extended radical pancreatoduo-
denectomy. The first results of this trial are expected in two
years from now.
In the meantime, it seems that we are dealing with a
battle of two principles. On the one hand, we have our
scientific conscience which relies solely on evidence-based
surgery and on the other hand, we have our professional
conscience which tells us ‘never to give up’. At this point,
we wish to compliment those who are exploring the field of
extended radical pancreatoduodenectomy for all their
efforts to push forward the frontier in what remains a dismal
disease.
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